Johnson & Johnson’s bispecific antibody Rybrevant Faspro won accelerated approval from the FDA for patients with head and neck cancer that has returned after prior chemotherapy and immunotherapy. The approval expands use beyond Rybrevant Faspro’s earlier indication in certain lung cancers. For manufacturers and clinicians, the key near-term impact is regulatory validation of the platform in a new solid-tumor setting, potentially reshaping positioning in refractory disease lines. The accelerated pathway also increases expectations for confirmatory evidence timing and real-world sequencing decisions across head and neck oncology. The update arrives as companies continue shifting bispecific development toward broader tumor types, with FDA timelines becoming a competitive differentiator for lead programs.